Sunshine Heart's CEO Departs As The Firm Faces Trial Challenges
This article was originally published in The Gray Sheet
The heart-assist device firm abruptly announced the departure of its CEO. Sunshine has faced multiple challenges, including slow enrollment and the need for protocol-ordered pause, with the pivotal trial for its C-Pulse system.
You may also be interested in...
The company has switched from pursuing a counterpulsation technology to focusing on a fully implantable neuromodulation device, and is now directing its full attention to the recently acquired Aquadex FlexFlow ultrafiltration system for heart failure, all in a period of about three-to-four months.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.